These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29700053)

  • 1. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
    Zizzari IG; Napoletano C; Botticelli A; Caponnetto S; Calabrò F; Gelibter A; Rughetti A; Ruscito I; Rahimi H; Rossi E; Schinzari G; Marchetti P; Nuti M
    Cancer Immunol Res; 2018 Jun; 6(6):711-722. PubMed ID: 29700053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells.
    Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
    Reguera-Nuñez E; Man S; Xu P; Kerbel RS
    Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.
    Rinchai D; Verzoni E; Huber V; Cova A; Squarcina P; De Cecco L; de Braud F; Ratta R; Dugo M; Lalli L; Vallacchi V; Rodolfo M; Roelands J; Castelli C; Chaussabel D; Procopio G; Bedognetti D; Rivoltini L
    Clin Transl Med; 2021 Jun; 11(6):e434. PubMed ID: 34185403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
    Bellmunt J; Esteban E; Del Muro XG; Sepúlveda JM; Maroto P; Gallardo E; Del Alba AG; Etxaniz O; Guix M; Larriba JLG; Arranz JA; Redrado M; Calvo A
    Eur Urol Oncol; 2021 Jun; 4(3):502-505. PubMed ID: 31477526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib Exerts
    Ocadlikova D; Lecciso M; Broto JM; Scotlandi K; Cavo M; Curti A; Palmerini E
    Front Immunol; 2021; 12():577766. PubMed ID: 33717062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
    Olaussen KA; Commo F; Tailler M; Lacroix L; Vitale I; Raza SQ; Richon C; Dessen P; Lazar V; Soria JC; Kroemer G
    Oncogene; 2009 Dec; 28(48):4249-60. PubMed ID: 19749798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
    Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
    Shablak A; Gilham DE; Hawkins RE; Elkord E
    Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
    Hirsch L; Flippot R; Escudier B; Albiges L
    Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.